The decision was made after Enzon decided to redirect its efforts onto new business objectives, including a greater focus on cancer, the companies said. Enzon and Micromet had been collaborating since April 2002.
The companies said that the termination of their collaboration does not affect their other agreements, including a cross-license agreement between the parties and a marketing agreement under which Micromet is the exclusive marketer of the companies' combined intellectual property estate in the field of single-chain antibody technology.